Key result
Childhood cancer survivors had a significantly higher prevalence of metabolic syndrome compared to a national reference group (13.6% vs 9.4%, p=0.028).
Why the study?
Managing metabolic syndrome is crucial for childhood cancer survivors, prompting investigation into the prevalence and predictive factors of its components.
Is the prevalence of metabolic syndrome higher in childhood cancer survivors compared to a reference population, and what are the risk factors?
Cross-Sectional (n=5,344)
Is the prevalence of metabolic syndrome higher in childhood cancer survivors compared to a reference population, and what are the risk factors?
Absolute Event Rate: 13.6% vs 9.4%
p-value: p=0.028
Childhood cancer survivors have a significantly higher prevalence of metabolic syndrome and dyslipidemia compared to the general population, particularly those with growth hormone deficiency or prior cranial radiotherapy.
May support targeted screening in survivors with growth hormone deficiency or cranial radiotherapy; hypothesis-generating pending prospective studies.
Purpose: It is crucial for childhood cancer survivors (CCSs) to manage metabolic syndrome. The prevalence and predictive factors of metabolic syndrome components in CCSs were investigated. Methods: This study included CCSs who were diagnosed with cancer under the age of 20 and completed therapy more than 1 year ago. The anthropometric and laboratory data were obtained from the medical records retrospectively. The reference group was extracted from the Korea National Health and Nutrition Examination Survey (2016–2019). Results: Of the participants, 29.1% (75 of 258) of the CCSs and 26.4% (1339 of 5081) of the reference group were obese. Blood pressure and triglyceride levels were significantly different in the two groups. Metabolic syndrome was identified in 35 of 258 (13.6%) patients. The reference group showed a 9.4% of prevalence (480 of 5086) ( p = 0.028). A total of 127 of 230 (59.6%) met at least one of the dyslipidemia criteria. In multivariate analysis, current age and growth hormone deficiency (GHD) (OR = 5.905) were significant prognostic factors for dyslipidemia, and GHD was a significant prognostic factor for hypertriglyceridemia (OR = 2.864, p = 0.0316) and hypercholesterolemia (OR = 3.053, p = 0.0467). Cranial radiotherapy (RT) was a prognostic variable for hyper low-density lipoprotein cholesterolemia (OR = 2.866, p = 0.0032). Conclusions: The frequency of metabolic syndrome was higher in CCSs compared with the reference group. Dyslipidemia was common in CCSs with clinical parameters such as GHD and cranial RT. Risk-based long-term follow-up is needed, and early intervention is required for CCSs.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2022) conducted a cross-sectional in Childhood cancer survivors (n=5,344). Childhood cancer survivorship vs. General population reference group was evaluated on Metabolic syndrome (p=0.028). Childhood cancer survivors had a significantly higher prevalence of metabolic syndrome compared to a national reference group (13.6% vs 9.4%, p=0.028).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: